Skip to main content

Table 1 Patients’ characteristics and TP53 mutation in 132 patients with AML/ MDS

From: TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

Factors Number of AML/ MDS patients
N (%)
TP53 mutated patients
N (%)
P
Age, range 16–93 years (N = 132)    0.575
 < 60 years 69 (52.3) 6/69 (8.7)  
> 60 years 63 (47.7) 8//63 (12.7)  
Disease (N = 132)    0.003
 De novo AML 87 (65.9) 8/87 (9.2)  
 Secondary AML 17 (12.9) 3/17 (17.6)  
 MDS (excess blast) 24 (18.2) 1/24 (4.2)  
 T-AML/MDS 4 (3.0) 2/4 (50)  
White blood cell count in AML patients (N = 107)    0.563
 < 100,000/μL 88 (82.2) 12/88 (13.6)  
> 100,000/μL 19 (17.8) 0/19 (0)  
Chromosome analysis (N = 132)    0.016
 Abnormal 67 (50.8) 12//67 (17.9)  
 Normal 65 (49.2) 2/65 (3.1)  
Cytogenetic risk (N = 132)    0.01
 Favorable 6 (4.5) 0/6 (0)  
 Intermediate 89 (67.4) 5/89 (5.6)  
 Unfavorable 37 (28) 9/37 (24.3)  
Complex chromosome (N = 132)    0.004
 Yes 24 (18.2) 7/24 (29.2)  
 No 108 (81.8) 7/108 (6.5)  
Complex with monosomy karyotype (N = 132)    0.008
 Yes 14 (10.6) 5/14 (35.7)  
 No 118 (89.4) 9/118 (7.6)  
Complex with del5/−5 or del7/−7 (N = 132)    0.026
 Yes 12 (9.0) 4/12 (33.3)  
 No 120 (91.0) 10/120 (8.3)  
Monosomy (N = 132)    0.002
 Yes 21 (15.9) 7/21 (33.3)  
 No 111 (84.1) 7/111 (6.3)  
Gene mutation (N = 107 AML patients)    0.893
 FLT3-ITD 13 (12.1) 3/13 (23)  
 NPM1 26 (24.3) 3/26 (11.5)  
 CEBPA 9 (8.4) 0/9 (0)  
 No mutation 80 (74.8) 10/80 (12.5)